|
US20010031264A1
(en)
|
1996-01-25 |
2001-10-18 |
Andrew Segal |
Vaccine compositions and methods of modulating immune responses
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
SI1629011T1
(sl)
|
2003-05-31 |
2010-05-31 |
Micromet Ag |
Humane molekule za vezavo anti hu cd
|
|
BRPI0713421A2
(pt)
|
2006-06-14 |
2012-03-13 |
Imclone Systems Incorporated |
Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
ES2650224T3
(es)
|
2007-08-21 |
2018-01-17 |
Amgen, Inc. |
Proteínas de unión al antígeno C-FMS humano
|
|
TW200927761A
(en)
*
|
2007-09-26 |
2009-07-01 |
U3 Pharma Ag |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
JP6126782B2
(ja)
|
2008-10-01 |
2017-05-10 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
|
|
PL2352763T5
(pl)
|
2008-10-01 |
2023-01-30 |
Amgen Research (Munich) Gmbh |
Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
WO2011123830A2
(en)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
EP2820047B1
(en)
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Long life polypeptide binding molecules
|
|
CN104540518A
(zh)
|
2012-04-27 |
2015-04-22 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
WO2014012085A2
(en)
*
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
|
CN104271602B
(zh)
|
2012-11-21 |
2020-08-21 |
武汉友芝友生物制药有限公司 |
双特异性抗体
|
|
CN105283201B
(zh)
|
2013-03-14 |
2019-08-02 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
|
WO2014140358A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
AU2015323313B2
(en)
|
2014-09-25 |
2021-04-01 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
MX2017006016A
(es)
|
2014-11-11 |
2017-06-19 |
Amunix Operating Inc |
Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
EP3322715B1
(en)
|
2015-07-14 |
2023-10-18 |
BioNTech SE |
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
KR20230041739A
(ko)
|
2016-03-08 |
2023-03-24 |
매버릭 테라퓨틱스, 인크. |
유도성 결합 단백질 및 사용 방법
|
|
HRP20230528T1
(hr)
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
CN116987189A
(zh)
|
2016-05-20 |
2023-11-03 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
MX2019004775A
(es)
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
|
EP3544629A4
(en)
|
2016-11-23 |
2020-06-17 |
Harpoon Therapeutics, Inc. |
PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
|
|
US11690919B2
(en)
|
2017-01-17 |
2023-07-04 |
The Texas A&M University System |
Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
|
|
WO2018209304A1
(en)
*
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
IL302613B2
(en)
|
2017-09-08 |
2025-04-01 |
Maverick Therapeutics Inc |
Binding proteins are activated under limited conditions
|
|
CA3287794A1
(en)
|
2017-10-14 |
2025-10-27 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CN111433224B
(zh)
|
2017-11-17 |
2024-03-19 |
南京传奇生物科技有限公司 |
抗pd-l1的单结构域抗体及其变体
|
|
EP3728326A4
(en)
*
|
2017-12-21 |
2021-12-15 |
Amunix Pharmaceuticals, Inc. |
SEPARATING SEGMENTS AND BINDING COMPOSITIONS THEREFORE
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス，インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
EP3794044A4
(en)
*
|
2018-05-14 |
2022-02-16 |
Harpoon Therapeutics, Inc. |
DOUBLE BINDING UNIT
|
|
WO2020033837A1
(en)
|
2018-08-09 |
2020-02-13 |
Maverick Therapeutics, Inc. |
Coexpression and purification method of conditionally activated binding proteins
|
|
US20230132385A9
(en)
*
|
2018-09-20 |
2023-04-27 |
Tikcro Technologies Ltd. |
Antibodies specific to ctla-4 and uses thereof
|
|
CN120463822A
(zh)
|
2018-09-27 |
2025-08-12 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
MY205459A
(en)
|
2018-12-06 |
2024-10-22 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|
|
CA3125302A1
(en)
*
|
2019-01-18 |
2020-07-23 |
University Of Southern California |
Methods and compositions to improve the safety and efficacy of cellular therapies
|
|
US20220144949A1
(en)
|
2019-03-05 |
2022-05-12 |
Takeda Pharmaceutical Limited Company |
CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
EP3966250A4
(en)
*
|
2019-05-07 |
2022-11-23 |
Immunorizon Ltd. |
PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
|
|
CN114423499A
(zh)
|
2019-06-06 |
2022-04-29 |
佳努克斯治疗公司 |
与肿瘤激活的t细胞衔接子相关的组合物和方法
|
|
US20230121775A1
(en)
|
2019-06-26 |
2023-04-20 |
Amunix Pharmaceuticals, Inc. |
Cd3 antigen binding fragments and compositions comprising same
|
|
WO2022035866A1
(en)
|
2020-08-11 |
2022-02-17 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
EP4228694A4
(en)
|
2020-10-15 |
2024-12-18 |
Janux Therapeutics, Inc. |
ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF
|
|
WO2022098909A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Harpoon Therapeutics, Inc. |
Epcam targeting trispecific protein for treatment of cancer
|
|
EP4259177A4
(en)
|
2020-12-08 |
2024-11-06 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
CN117042788A
(zh)
|
2020-12-08 |
2023-11-10 |
佳努克斯治疗公司 |
半衰期延长组合物和方法
|
|
AU2021396172A1
(en)
|
2020-12-09 |
2023-07-06 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|